United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares

Posted by on May 28th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $572.38, for a total value of $4,579,040.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,188,830.94. This represents a 16.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Down 1.3%

Shares of NASDAQ UTHR opened at $570.75 on Thursday. The business’s 50 day moving average is $565.54 and its two-hundred day moving average is $514.75. The company has a market cap of $24.23 billion, a P/E ratio of 21.07, a P/E/G ratio of 1.87 and a beta of 0.60. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $6.63 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Arjuna Capital raised its stake in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 18 shares in the last quarter. Clearstead Advisors LLC raised its stake in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares in the last quarter. Sage Rhino Capital LLC grew its stake in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC grew its stake in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the period. Finally, Meeder Advisory Services Inc. grew its stake in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on UTHR shares. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $619.42.

Check Out Our Latest Stock Analysis on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.